lunes, 31 de agosto de 2015

Relación informativa de medicamentos afectados por las deducciones establecidas en el Real Decreto Ley 8/2010 (Septiembre 2015)


Relación de medicamentos afectados por las deducciones en la facturación sobre el PVP del 15%, 7,5% y del 4% para medicamentos huérfanos, establecidas en los artículo 8, 9 y 10 del Real Decreto Ley 8/2010, modificado por el Real Decreto Ley 9/2011.

Nota informativa publicada en la Web del Mº de Sanidad (MSSSI) www.msssi.gob.es (apartado PROFESIONALES/ FARMACIA).

Updated guidance on good clinical practice released for consultation

21/08/2015

Comments on the ICH E6 addendum are invited until 3 February 2016

The European Medicines Agency (EMA) has released an addendum to the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) E6 (R2) guideline on good clinical practice (GCP) for a six-month public consultation.
Stakeholders are invited to send their comments using the template provided by 3 February 2016. The completed template should be sent to ich@ema.europa.eu.
GCP is an international ethical and scientific quality standard for designing, recording and reporting trials that involve the participation of human subjects. Compliance with this standard provides public assurance that the rights, safety and wellbeing of trial subjects are protected and that clinical-trial data are credible.
The current ICH E6 guideline provides a unified standard on GCP. It describes responsibilities and activities of sponsors, monitors, investigators and ethics committees.
Since the finalisation of this guideline in 1996, the scale, complexity and costs ofclinical trials have increased. Developments in technology and risk management processes offer new opportunities to increase their efficiency by allowing sponsors to focus on relevant activities. With this in mind, the guideline has been amended to:
  • encourage implementation of improved and more efficient approaches to clinical trialdesign, conduct, oversight, recording and reporting while continuing to ensure the protection of clinical trial participants, and data integrity;
  • update standards regarding electronic records and essential documents intended to increase the quality and efficacy of clinical trials.
Updates have been made to several sections of the guideline and are highlighted in the document.

martes, 18 de agosto de 2015

Circular 3/2015: Información sobre prevención de riesgos de medicamentos de uso humano (materiales informativos sobre seguridad)


La presente circular tiene como objeto establecer el procedimiento y criterios básicos que deberán seguir los Titulares de la Autorización de Comercialización (TAC) y los representantes del TAC (ReTAC) para obtener de la AEMPS la autorización para distribuir la información sobre prevención de riesgos o materiales informativos sobre seguridad.

Documento adjunto: circular 3/2015

miércoles, 12 de agosto de 2015


A post-authorisation safety study (PASS) is defined in Directive 2001/83/EC (DIR) Art 1(15) as any study relating to an authorised medicinal product conducted with the aim of identifying, characterising or quantifying a safety hazard, confirming the safety profile of the medicinal product, or of measuring the effectiveness of risk management measures. This module concerns PASS which are clinical trials or non-interventional studies, with a main focus on non-interventional PASS. It does not address non-clinical safety studies.

Consultation start date 11/08/2015
Consultation end date 09/10/2015

See document: LINK

Boletín mensual del mes de julio de 2015

Recoge nuevos medicamentos, cambios de especial interés en medicamentos ya autorizados, información sobre seguridad y otra información de interés. En la sección de productos sanitarios, cosméticos y productos de cuidado personal se incluyen resúmenes de las notas informativas publicadas durante el mes.